top of page

21 start-ups reach EIT Health Catapult Final

Twenty-one start-ups from across Europe have secured their places at the EIT Health Catapult Final. The finalists represent the most promising European start-ups across biotech, medtech and digital health.

The EIT Health Catapult, currently in its sixth year, boosts the development of European health start-ups by exposing them to leading experts and international investors. Winners often go on to achieve impressive growth. Notably, two of last year’s winners recently celebrated acquisitions, following their success in 2020. Second in last year’s biotech category, PhagoMed, were acquired by BioNTech and Patchai were acquired by US-based Alira Health, having come third in digital health.

Dr. Kurt Höller, Director of Business Creation at EIT Health, said: “After the EIT Health Catapult success stories from the past two years, we are thrilled to announce 21 promising start-ups that will compete in our finals live on stage. We look forward to seeing what the winners go on to achieve with our support.”

Meet the finalists Biotech Podium finalists: Onena Medicines (Spain): makes antibody medicines that force drug resistant cancer stem cells to permanently grow old, rendering them incapable of sustaining and spreading cancer. SideROS (France): a preclinical stage biotech, developing small molecules targeting iron metabolism to fight cancer resistance, responsible for relapse and metastasis. SolasCure (UK): makes Aurase®, a hydrogel containing a safe, active, highly specific enzyme, isolated and cloned from medical maggots which promotes faster wound cleaning. Finalists (runners up): Arthex Biotech (Spain): a preclinical stage life sciences company focused on developing the next generation of RNA therapies to treat myotonic Dystrophy Type1. Asylia Diagnostics (Belgium): an artificial intelligence enabled in vitro diagnostics company, focused on optimising the clinical management of cancer patients treated by immune checkpoint inhibitors. Limula (Switzerland): saves lives by enabling widespread access to the latest generation of personalised cancer treatments. myNEO (Belgium): helps to unlock the potential of immunotherapy for every cancer patient using innovative biosimulation and AI heuristics.

Medtech Podium finalists: Leuko (Spain): develops PointCheck™, a device that can monitor white blood cells non-invasively. White blood cell monitoring is a first-line indicator in cancer chemotherapy and infection detection. Luminate Medical (Ireland): develops a novel technology to manage off-target drug delivery. Their product, Lily, provides a portable, patient-focused treatment to prevent chemo induced hair loss. Thinksono (Germany): created the world’s first software for automatic detection of deep vein thrombosis (DVT). DVT is the number one cause of preventable hospital death. Finalists (runners up): Arthrosave (Netherlands): offers a revolutionary procedure to preserve the knee joint for people with osteoarthritis, significantly reducing pain and improving function. BeFC (France): makes electricity with papers and enzymes. Their paper biofuel cells provide an eco-friendly and sustainable energy solution for low-power medical devices. FeelTect (Ireland): has developed Tight Alright, the first connected health platform for monitoring compression therapy; improving healing, reducing costs, and facilitating self-managed treatment. Orixha (France): aims to bring liquid ventilation’s clinical benefits to the ICUs to save critical care patients. Vent2Cool is developed to shield the brain and heart from reperfusion injury.

Digital Health Podium finalists: AZmed (France): develops AI-powered solutions improving radiologist’s productivity and diagnostics quality. Their first product Rayvolve detects all types of fractures on X-rays. Brightlobe (UK): has invented patent-pending technology that can assess and support a child’s brain development using clinically validated mobile games. Ebenbuild (Germany): develops simulation/AI software to generate data about patients’ lungs, enabling doctors to provide better personalised therapy for Acute Respiratory Distress Syndrome (ARDS). Finalists (runners up): Amara Therapeutics (UK): develops a prescription digital therapeutic platform, RiSolve, for the treatment of Overactive Bladder. Exheus (Spain): the first direct-to-consumer gene expression report that helps to optimise people’s health in a highly personalised way, by sequencing the RNA from a blood sample. Heaxel (Italy): develops icone, a connected network of robots which aids the neurorehabilitation of stroke patients fro